Does primary ICD therapy improve survival in the MADIT-II population?
Primary ICD therapy provides a sustained 8-year survival benefit in the MADIT-II population.
Our findings demonstrate a sustained 8-year survival benefit with primary ICD therapy in the MADIT-II population.
Goldenberg et al. (Tue,) studied this question.